Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Cancers, Free Full-Text

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

Nivolumab and Relatlimab for Advanced Melanoma - NCI

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity, Journal for ImmunoTherapy of Cancer

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

IJMS, Free Full-Text

Actualizaciòn en el tratamiento de metàstasis cerebrales por melanoma

Figure 3 from Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Nivolumab plus ipilimumab benefits patients with asymptomatic melanoma brain metastases

Immunotherapy: an emerging modality to checkmate brain metastasis, Molecular Cancer

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology